By VALIDOGEN GmbH
To get in touch with VTU Technology to show 25th BIO International how to Unlock Pichia, simply fill out the form below.
Subscribe to Supplier
VTU Technology to show 25th BIO International how to Unlock Pichia
Grambach, Austria: – Protein expression specialist VTU Technology will show potential partners at June’s high prestige BIO International Convention in Boston how to unlock the advantages of its leading-edge protein production platform, its Pichia pastoris recombinant expression technology.
Safe, clinically validated, well-characterized and CMC-ready Pichia pastoris protein production strains and processes for biopharmaceutical manufacturing
VTU will demonstrate how biopharma companies benefit from VTU´s CMC compliant technology platform for the safe and effective production of therapeutic candidates.
Pichia pastoris has been approved by major regulatory authorities for the production of biopharmaceuticals and, on top of that, several appealing features render the VTU Pichia platform well suited for the production of biologics. All components of VTU´s Pichia toolbox, which has already been used to produce proteins for clinical studies, are thoroughly characterized and full documentation is readily available to support regulatory filings for biologic candidates.
Furthermore, Pichia based protein production is no longer limited to non-glycosylated proteins. VTU offers boosted glycoprotein production by combining VTU´s Pichia technology with Pichia Glycoswitch®. Pichia Glycoswitch® enables the production of homogeneous and uniform glycoproteins with Man5- or other human-like glycoforms. The Picha GlycoSwitch® system is based on yeast strains that have been engineered to perform specific glycosylation steps at high fidelity.
Unlocking Pichia power
The VTU presence at the convention will be led by Head of Business Development, Dr. Thomas Purkarthofer, along with Roland Weis, Head of Operations.
“Once again, this important convention provides us with a great opportunity to reach out to a wide range of people and companies dealing with recombinant protein and biologics production, ranging from small biotechs to big pharma, diagnostics producers, along with food/feed, agro and chemical industries,” said Dr. Purkarthofer.
“We will show visitors how VTU addresses the multiple aspects of protein expression by increasing genetic diversity. A broad set of helper factors, platform strains and new concepts abolishes bottlenecks in transcription, translation, translocation, protein folding and secretion,” he added.
“Since our foundation in 2008, we have been continuously optimizing and expanding our Pichia technology to generate an unparalleled spectrum of exclusive tools and strategies to meet highly specific expression needs, now making it the broadest and most powerful Pichia pastoris protein production platform available anywhere,” Roland Weis noted.
About VTU Technology
VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression / production enabling highest productivities delivering up to 25 g/L of secreted protein (record productivities of 35 g/L) within a few weeks development time.
VTU´s yield-enhancing Pichia pastoris expression platform is based on its proprietary AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening and cultivation regime combined with excellent know-how in fermentation and downstream process development for maximization of product yield and overall process performance.
About BIO International 2018
The 25th Anniversary BIO International Convention (BIO) provides a week of intensive networking for biotechnology and pharma leaders to discover new opportunities and promising partnerships. It attracts more than 16,000 delegates involved in a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.
BIO International 2018 returns to Boston MA as a four -day event opening June 4 at the waterfront Boston Convention and Exhibition Center (BCEC). The convention will feature more than 35,000 face-to-face meetings for some 3,100 companies organised using the proprietary BIO One-on-One partnering™ system, as well as hundreds of individual company presentations, a program of world-renowned keynote speakers and some 20 Session Tracks.
A co-located trade show will feature more than 1,800 exhibitors from fields ranging from digital health and diagnostics to bioprocesses.
The event is organized by the Washington DC-based Biotechnology Innovation Organization with more information at: http://convention.bio.org/.